Formulary Watch Newsletter

To view this email as a web page, click here.

Gilead promises generic versions of hepatitis drug

After receiving FDA approval for a drug for chronic hepatitis B virus, Gilead Sciences said low-cost, generic versions would soon be available.

6 facts to know about ixekizumab

Ixekizumab is designed to specifically target IL-17A, a protein that plays a role in driving underlying inflammation in psoriasis.

Find out more

FDA warns about OTC antacids, antidiarrheal med

FDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn.

5 things to know about the HIV treatment Genvoya

Here are the top 5 things to know about Genvoya.

Nebivolol and valsartan combination for hypertension gets FDA approval

Nebivolol and valsartan is a fixed-dose combination of a beta blocker and angiotensin II receptor blocker for hypertension.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.

CONNECT